Together, this suggests that OPA1 mutations cause multiple organ abnormalities, including auditory neuropathy, peripheral neuropathy (apoptosis and ophthalmoplegia), cardiomyopathy and myopathy, suggesting that OPA1 could be a common target for treatment of mitochondria-related disorders. Here, OPA1 is linked to peripheral neuropathy.